How the themes are counted
One paper saying "this needs more study" tells you little. 52 separate papers raising the same open question is a finding about the field. The themes below are ordered by how many distinct papers raised them, most first, with "Other open questions" last. We count papers, not sentences, because one long paper can produce a dozen sentences on the same point.
Of the 369 studies in the library, 253 yielded at least one such sentence (455 from open-access full text, 49 from the abstract only). The rest either had no accessible text, or simply did not phrase an open question in a way we could quote without interpreting it — and we would rather miss one than invent one.
- The mechanism is not understood 52
- Measurement, definitions, assays and standardisation 51
- Real-world delivery, cost and access 51
- Who was studied - diversity and generalisability 49
- Biomarker-defined, genetic and clinical subgroups 47
- Follow-up is too short to know if the effect lasts 42
- Bigger samples and independent replication 27
- Specific exposures, drugs and programmes named as worth testing 25
- Whether the association is causal is still open 18
- Long-term safety and harms 14
- The right dose, intensity, frequency and type is unresolved 13
- When in life to intervene 13
- Better treatments and interventions still need developing 2
- Combination and multidomain approaches 1
- Other open questions 35
Where the papers disagree
These are not gaps everyone agrees on. In each pair below, two papers in this library point in different directions about what should happen next. Both quotes are verbatim.
Physical activity: is the open question whether it works, or which kind works best?
“Furthermore, our results on cognitive decline are in accordance with other longitudinal studies showing no association between physical activity and cognitive ageing.”
Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study. · BMJ, 2017
“Future studies are needed to confirm current findings, explore the effects of different types of exercise training on outcomes in individuals with SVCI, identify moderators of exercise efficacy (e.g., biological sex), and examine the distinct mechanisms by which each exercise modality may exert its benefits.”
Resistance training and subcortical vascular cognitive impairment: A 12-month randomized trial. · Alzheimer's & Dementia, 2026
Both papers are asking for more exercise research, but not the same research. One reports no association with cognitive decline at all; the other treats the benefit as established enough that the next question is which modality and which mechanism.
Vision and hearing: replicate the association first, or start rolling out screening?
“While some US cohort studies have observed a significant association between vision impairment and dementia risk [ , ], other US and European longitudinal studies have failed to replicate these findings [ – ].”
“Future studies should test whether vision screening or cataract surgery in those with co-occurring dementia risk factors are effective at reducing the risk of dementia.”
Visual Impairment, Eye Conditions, and Diagnoses of Neurodegeneration and Dementia. · JAMA Network Open, 2024
The same body of evidence is read two ways: one review notes that the vision-dementia association has failed to replicate across cohorts, while the proposed next steps elsewhere assume it holds and move to testing or implementing screening.
Repeat scans and tests to monitor disease: not supported, or the obvious next study?
“Cross‐sectional and longitudinal studies do not support the use of a subsequent amyloid PET to assess the degree of cognitive impairment or to monitor the rate of progression of the underlying AD pathological process.”
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. · Alzheimer's & Dementia, 2025
“Additionally, future research should explore how the test can monitor disease as it progresses or how treatment responds with longitudinal studies [ ] .”
FDA approval of the Lumipulse G PTau217/β-amyloid 1-42 plasma ratio test: a new era in accessible Alzheimer's diagnosis. · Annals of Medicine and Surgery, 2025
The appropriate-use criteria for amyloid and tau PET state that the existing longitudinal evidence does not support repeat amyloid imaging for monitoring. An editorial on the newly approved blood test proposes studying exactly that use for blood biomarkers. Different tests - but the same unresolved question about whether repeat measurement tracks anything useful.
The mechanism is not understood 52 papers
The effect is measurable; the biology behind it is not settled. — 58 quoted sentences from 52 separate papers.
-
“Further study of CAA‐ri may therefore offer a valuable model for exploring the pathophysiological mechanisms of ARIA.”
— Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.; van Etten ES, et al.; Alzheimer's & Dementia, 2026. review Spontaneous hemorrhages and edema · source text
-
“Though the mechanism remains unclear, ARM may act as a defense against beta-amyloid accumulation through barrier formation and increased phagocytosis.”
— APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer's disease.; Nguyen AT, Wang K, Hu G, Wang X, Miao Z, Azevedo JA, Suh E, Van Deerlin VM, Choi D, Roeder K, Li M, Lee EB; Acta Neuropathologica, 2020. Discussion · source text
-
“Lastly, starting from our results, future studies need to more deeply explore the underlying biological mechanisms through which the MedDiet may influence dementia, and therefore comparing the effectiveness of the MedDiet with other dietary patterns in reducing the risk of dementia.”
— Association between Mediterranean diet and dementia and Alzheimer disease: a systematic review with meta-analysis.; Nucci D, Sommariva A, Degoni LM, Gallo G, Mancarella M, Natarelli F, et al.; Aging Clinical and Experimental Research, 2024. meta-analysis Implications for policy, practice and future research · source text
-
“Future studies are needed to better elucidate these mechanisms.”
— Long-term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: An up to 10-year follow-up study.; Xu H, Habich A, Ferreira D, Elisabet L, Westman E, Eriksdotter M; Alzheimer's & Dementia, 2024. DISCUSSION · source text
-
“The role of prolonged sleep duration in the development of dementia remains unclear and is closely associated with age.”
— Sleep disorders and the risk of cognitive decline or dementia: an updated systematic review and meta-analysis of longitudinal studies.; Zhang J, Ou J, Lu X, Wang T, Dang W, Ding L, Liu Y, Xu J, Yan B, Yu H; Journal of Neurology, 2025. meta-analysis Sleep duration and cognitive disorders · source text
-
“Further research into the interaction between diet and genetics on dementia risk is therefore warranted.”
— Mediterranean diet adherence is associated with lower dementia risk, independent of genetic predisposition: findings from the UK Biobank prospective cohort study.; Shannon OM, Ranson JM, Gregory S, Macpherson H, Milte C, Lentjes M, et al.; BMC Medicine, 2023. Discussion · source text
Show the other 52 quotes in this theme
Measurement, definitions, assays and standardisation 51 papers
Different teams measuring different things and calling them the same name. — 57 quoted sentences from 51 separate papers.
-
“Though it identified many reasons to involve specialist palliative care, the lack of consensus highlighted the need for further study on a set of consensus referral criteria that may streamline referrals to specialist palliative care in a timely manner to optimize patient and caregiver outcomes.”
— Referral Criteria for Specialist Palliative Care for Patients With Dementia.; Chang YK, Philip J, van der Steen JT, Van den Block L, Hum AYM, Pérez-Cruz PE, Paiva C, Mori M, Chen PJ, Agar MR, et al.; JAMA Network Open, 2025. Introduction · source text
-
“The relative roles of SWI versus GRE for the detection of microhemorrhages warrant further evaluation.”
— Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.; van Etten ES, et al.; Alzheimer's & Dementia, 2026. review Outstanding challenges and future directions · source text
-
“Future studies should use modeling techniques that can better account for these other types of societal costs.”
— Cost of care for Alzheimer's disease and related dementias in the United States: 2016 to 2060.; Nandi A, Counts N, Bröker J, Malik S, Chen S, Han R, Klusty J, Seligman B, Tortorice D, Vigo D, Bloom DE; npj Aging, 2024. Discussion · source text
-
“Although we found some evidence of differences in hazards for stroke, pneumonia, and acute kidney injury between male and female antipsychotic users, further research is needed to validate these findings.”
— Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study.; Mok PLH, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA, Camacho EM, van Staa T, Avery AJ, Ashcroft DM; BMJ, 2024. Strengths and limitations of this study · source text
-
“Future studies should aim to adopt standardized diagnostic frameworks incorporating objective sleep measures (e.g., polysomnography or actigraphy) to minimize variability in sleep disorder definitions.”
— Sleep disorders and the risk of cognitive decline or dementia: an updated systematic review and meta-analysis of longitudinal studies.; Zhang J, Ou J, Lu X, Wang T, Dang W, Ding L, Liu Y, Xu J, Yan B, Yu H; Journal of Neurology, 2025. meta-analysis Publication bias and heterogeneity · source text
-
“If future studies confirm that Aβ positivity affects SAA results, it is then crucial to develop SAA protocols that are robust to Aβ co-pathology.”
— Diagnostic Performance of the α-Synuclein Seed Amplification Assay for Dementia With Lewy Bodies: A Comparison Across 4 Laboratories.; Kumar R, Gravett S, Jelic V, Lange J, Oftedal L, Ciullini A, Bacınoğlu MB, De Luca CMG, Hamied L, Birck C, et al.; Neurology, 2026. Discussion · source text
Show the other 51 quotes in this theme
Real-world delivery, cost and access 51 papers
Whether a result that held in a trial survives contact with an ordinary clinic. — 52 quoted sentences from 51 separate papers.
-
“Further research is necessary not only to validate their use in the primary and specialist care settings but also to evaluate for possible impediments to effective implementation.”
— Referral Criteria for Specialist Palliative Care for Patients With Dementia.; Chang YK, Philip J, van der Steen JT, Van den Block L, Hum AYM, Pérez-Cruz PE, Paiva C, Mori M, Chen PJ, Agar MR, et al.; JAMA Network Open, 2025. Discussion · source text
-
“Clinicians will need to be prepared to engage in a multistep process of evaluating appropriateness for treatment, with each step involving education and counseling.”
— Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.; van Etten ES, et al.; Alzheimer's & Dementia, 2026. review RISK/BENEFIT CONVERSATIONS IN TREATMENT DECISION‐MAKING AND PATIENT PERSPECTIVE · source text
-
“Future studies should use modeling techniques that can better account for these other types of societal costs.”
— Cost of care for Alzheimer's disease and related dementias in the United States: 2016 to 2060.; Nandi A, Counts N, Bröker J, Malik S, Chen S, Han R, Klusty J, Seligman B, Tortorice D, Vigo D, Bloom DE; npj Aging, 2024. Discussion · source text
-
“Further research is needed into safer drug treatment of behavioural and psychological symptoms of dementia and more efficacious, easy to deliver, initial non-drug treatments.”
— Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study.; Mok PLH, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA, Camacho EM, van Staa T, Avery AJ, Ashcroft DM; BMJ, 2024. Policy implications · source text
-
“The next steps will be to establish the most effective, cost-effective, and feasible strategies for reducing these risks, that can be sustained within local contexts and achieve the best impacts, at the population level, in the short, medium, and long term.”
— Population attributable fractions of modifiable risk factors for dementia: a systematic review and meta-analysis.; Stephan BCM, Cochrane L, Kafadar AH, Brain J, Burton E, Myers B, et al.; Lancet Healthy Longevity, 2024. meta-analysis Discussion · source text
-
“Future studies should, where possible, incorporate objective measures of hearing aid benefit—such as aided audiometry, speech-in-noise tests, or even real-world data logging of device use—to validate and extend our findings based on self-report.”
— Hearing aid effectiveness and probable dementia risk across 33 countries: A pooled analysis of seven cohorts.; Jiang F, Dong Q, Jayakody DMP, Chen X, Mueller C, Wu B, et al.; Cell Reports Medicine, 2026. Discussion · source text
Show the other 46 quotes in this theme
-
“This trial introduces two key innovations relevant to the feasibility, safety and efficacy to be considered for future studies: the use of an oromucosal spray for drug delivery and the application of cannabinoids in dementia care in a dementia cohort with predefined nonpain-related agitation.”
— Sativex (nabiximols) for the treatment of Agitation & Aggression in Alzheimer's dementia in UK nursing homes: a randomised, double-blind, placebo-controlled feasibility trial.; Age and Ageing, 2025. Discussion
-
“Future studies might combine different administrative data sources (eg, pharmaceutical, primary care, aged care) to improve case detection and reduce the potential for bias.”
— Delirium and incident dementia in hospital patients in New South Wales, Australia: retrospective cohort study.; BMJ, 2024. Strengths and limitations of this study
-
“Further studies should be carried out investigating this type of treatment but increasing its frequency, as it is currently not extensively applied (leaving much of its implementation to be carried out by family members thus in an unsupervised manner).”
— The efficacy of cognitive stimulation, cognitive training, and cognitive rehabilitation for people living with dementia: a systematic review and meta-analysis.; GeroScience, 2024. Future directions
-
“Opportunities to mitigate discordant perceptions in perceived risk warrant further exploration, particularly if APOE disclosure becomes a routine part of clinical practice.”
— Impact of learning APOE genotype on cognitively unimpaired adults: a pre-screening cohort study of the Alzheimer's Prevention Initiative Generation Study 1.; The Lancet Healthy Longevity, 2025. Discussion
-
“Future studies evaluating healthcare utilization, particularly the use of psychotropic medications and acute medical care resources, would be highly informative to policy makers and clinicians, especially given concomitant changes in Medicaid dual eligibility owing to the Affordable Care Act.”
— Incidence and prevalence of dementia among US Medicare beneficiaries, 2015-21: population based study.; BMJ, 2025. Unanswered questions and future research
-
“One recent feasibility study examined the effect of daily internet-based conversational interactions on cognitive decline in people with mild cognitive impairment, finding better verbal fluency at 12-week follow-up in those who received the intervention compared to the control group [ ], and future studies should examine the feasibility of increasing social contact and its effect on cognition and dementia risk with longer follow-up.”
— Association of social contact with dementia and cognition: 28-year follow-up of the Whitehall II cohort study.; PLoS Medicine, 2019. Clinical implications and future research
-
“Lower diagnosis rates in low-income settings than in high-income settings and gaps in the availability of resources for the management of neuropsychiatric symptoms of dementia will be important to address. , , Evidence suggests that hospitalisation rates are higher among those with dementia than among those without dementia, and health systems need to be prepared for the expected increases in service use that will accompany increases in the number of people with dementia.”
— Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019.; The Lancet Public Health, 2022. Discussion
-
“While prices for some commercially available BBM tests have been reported, further research is needed to evaluate their relative cost and cost‐effectiveness in various settings.”
— Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings.; Alzheimer's & Dementia, 2025. Research needs
-
“Although much progress has been made in the clinical implementation of amyloid and tau PET, there are still many knowledge gaps that should serve as groundwork for future work.”
— Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.; Alzheimer's & Dementia, 2025. FURTHER RESEARCH QUESTIONS
-
“Clinicians need to be cautious in recommending escitalopram as an alternative to citalopram for this condition.”
— Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial.; Nature Medicine, 2025. abstract only
-
“Future studies should more fully examine whether these criteria are applicable in those settings, as well as focus on modification and implementation to effectively use these criteria as a screening tool in primary and specialist care practices.”
— Referral Criteria for Specialist Palliative Care for Patients With Dementia.; JAMA Network Open, 2025. Limitations
-
“For future work, validation using wearable devices is needed to ensure broader generalizability and support clinical implementation, and further investigation is warranted to determine how sleep microstructures interact with macrostructural measures.”
— Machine Learning-Based Sleep Electroencephalographic Brain Age Index and Dementia Risk: An Individual Participant Data Meta-Analysis; JAMA network open, 2026. discussion
-
“Future dementia prevention trials should consider how to capture the broader societal and informal care costs to enhance the relevance of findings for prevention-focused policy decisions.”
— Cost utility and cost-effectiveness of the APPLE-Tree programme: Active Prevention in People at risk of dementia through Lifestyle, bEhaviour change and Technology to build REsiliEnce: economic evaluation embedded within a randomised controlled trial; Age and ageing, 2026. discussion
-
“Further research incorporating real‐world outcomes and disaggregated analyses by geography and socioeconomic status will be essential to inform equitable and evidence‐based policy decisions in this space.”
— Cost-Effectiveness of Donanemab for Early Alzheimer Disease in Australia; The Medical journal of Australia, 2026. conclusion
-
“Regardless, before considering wide-scale implementation, further studies are warranted to validate long-term effectiveness and clarify causal mechanisms in real-world settings.”
— Cost-effectiveness of multimodal intervention for the prevention of dementia in Japan; The journal of prevention of Alzheimer's disease, 2026. conclusion
-
“Future research should evaluate the longer term and broader health and economic impact of progression (e.g. indirect societal costs) ideally in a real-world population of individuals with cognitively unimpaired AD and the impact of future effective disease-modifying therapies for avoiding increased costs observed with progression of cognitively unimpaired AD.”
— Increase in healthcare utilization and Medicare payment with progression of preclinical Alzheimer's disease; Journal of Prevention of Alzheimer's Disease, 2026. conclusion
-
“Continued efforts to test real-world populations with gold-standard pathology are needed to establish whether eGFR-adjusted plasma values improve classification accuracy and interpretation.”
— Electronic Health Records to Test Multimorbidity Influences to Plasma Biomarker Interpretation for Alzheimer's Disease; Annals of neurology, 2026. discussion
-
“Additional studies are needed to examine the impact of blood tests with higher specificity, such as high‐performing p‐tau217 assays, in both primary and specialty care.”
— Study of the utility and impact of a plasma p-tau181 Alzheimer's biomarker (SUITABLE); Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2026. discussion
-
“Biomarker performance and their accessibility and feasibility outside the research setting should also be investigated further.”
— A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests; Brain, 2025. discussion
-
“Future studies should evaluate pTau217-based workflows and the influence of BBM on patient management across broader clinical settings, preferably in a randomized manner.”
— Plasma Alzheimer Biomarkers and Diagnostic Decision-Making in Memory Clinics; JAMA Network Open, 2026. conclusion
-
“Further research should explore the impact of multiple IRA policies on OOP drug expenditures.”
— Changes in Out-of-Pocket Drug Expenditures Among Medicare Beneficiaries With Dementia Under the Inflation Reduction Act: A Simulation Study; Value in Health, 2025. discussion
-
“Moreover, future studies should integrate the costs of informal care into the cost estimates.”
— Costs of Care in Relation to Alzheimer's Disease Severity in Sweden: A National Registry-Based Cohort Study; PharmacoEconomics, 2025. discussion
-
“Further research is urgently needed to explore the drivers of informal care provision in the early stages and to clarify the role of biological and modifiable risk factors in shaping healthcare costs over time.”
— The economic burden of subjective cognitive decline, mild cognitive impairment and Alzheimer's dementia: excess costs and associated clinical and risk factors; Alzheimer's research & therapy, 2025. conclusion
-
“Model-based analyses have provided valuable information, and we hope future economic evaluations will incorporate more real-world data from clinical trials.”
— Cost-effectiveness of testing biofluid biomarkers to diagnose Alzheimer's disease: a systematic review; European Journal of Health Economics, 2026. conclusion
-
“Whether the nonmonotonical differences in inpatient care reflect a shift from specialist medical care to primary care in severe AD dementia stage warrants further investigation.”
— Utilization and Lifetime Costs of Formal Care for Alzheimer's Disease Dementia in Sweden; PharmacoEconomics, 2026. discussion
-
“Translation into clinical practice, however, will require addressing variability in PRS performance across ancestries, limited integration of genetic data into clinical workflows and the absence of standardized thresholds for clinical interpretation.”
— A multiancestry polygenic risk score for Alzheimer's disease is associated with cognitive decline and neuropathological hallmarks in diverse populations; Nature genetics, 2026. discussion
-
“Another limitation is that most of the findings from the included studies come from specialized settings with specific participant groups, which limits their generalizability to what is typically observed in routine clinical practice among individuals with cognitive impairment.”
— Blood-based biomarkers for detecting Alzheimer's disease pathology in cognitively impaired individuals within specialized care settings: A systematic review and meta-analysis; Alzheimer's & Dementia, 2025. discussion
-
“Characterizing this tradeoff between health systems costs (mainly nursing facility costs) and unpaid care is important, because several policies have been put in place to rebalance Medicaid long-term services and supports away from institutionalization and toward home and community-based services.”
— The costs of dementia care by US state: Medical spending and the cost of unpaid caregiving; Journal of Alzheimer's Disease, 2025. discussion
-
“While we are unable to quantify these “secondary” impacts of caregiving for caregivers’ and their employers’ costs, we recognize them as important cost elements that the future work needs to account for as data become available.”
— Current and Future Replacement and Opportunity Costs of Family Caregiving for Older Americans With and Without Dementia; Innovation in Aging, 2025. discussion
-
“Future research should investigate our findings in the context of Medicare Advantage, which represents a substantial and growing proportion of Medicare beneficiaries.”
— Racial and ethnic differences in disease course Medicare expenditures for beneficiaries with dementia; Journal of the American Geriatrics Society, 2024. discussion
-
“However, whether CDCM leads to better preparation for institutionalization should be investigated to support the community-dwelling living situation as long as possible and make institutionalizations as smooth as possible.”
— Clinical Outcomes and Cost-Effectiveness of Collaborative Dementia Care: A Secondary Analysis of a Cluster Randomized Clinical Trial; JAMA Network Open, 2024. discussion
-
“Further implementation studies with larger samples, extended intervention periods, longer observational periods, and varying settings are needed to monitor the translation.”
— Efficacy and cost-effectiveness of extended nursing roles in dementia care: Results of the cluster-randomized trial InDePendent; Alzheimer's & Dementia, 2025. conclusion
-
“Future research should validate these model-based projections using real-world data and explore the use of denominators other than confirmed cases with early-stage AD on value-based prices.”
— Estimation of the value-based price of a blood test for Alzheimer's disease pathology in primary and specialty care in the U.S; Journal of Prevention of Alzheimer's Disease, 2025. conclusion
-
“Renewed efforts to track and evaluate medication use in hospice are essential to guide evidence-based practice, inform policy, and protect patient safety.”
— Benzodiazepine or Antipsychotic Use and Mortality Risk Among Patients With Dementia in Hospice Care; JAMA Network Open, 2025. discussion
-
“Future analyses will compare change in the CDR-SB in patients treated with lecanemab for 18 months and untreated patients matched for key clinical characteristics.”
— Lecanemab Treatment in a Specialty Memory Clinic; JAMA Neurology, 2025. discussion
-
“Future work should investigate longer‐term clinical and caregiver outcomes and test the scalability and cultural adaptability of PLAN across different settings, while refining strategies to strengthen caregiver psychosocial support.”
— Efficacy of a language-concordant community health worker intervention to improve community-to-clinic linkage for dementia care: results of the randomized trial PLAN; Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. conclusion
-
“Future research should develop and evaluate models that support caregivers in their new role of managing treatment delivery.”
— Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer's Treatments with Different Duration and Route of Administration; Journal of Prevention of Alzheimer's Disease, 2024. conclusion
-
“Further validation is needed to evaluate the diagnostic accuracy of the Mini-Cog in the preoperative setting to determine if the Mini-Cog can predict postoperative outcomes such as delirium, morbidity, and mortality.”
— The diagnostic accuracy of the Mini-Cog screening tool for the detection of cognitive impairment—A systematic review and meta-analysis; PLOS ONE, 2024. discussion
-
“Context-specific evidence is needed to understand which domains and promotion strategies are most feasible and effective, and under what conditions, across countries with distinct physical activity profiles and structural constraints.”
— Domain-specific physical activity levels and risk of dementia: a systematic review and meta-analysis; The Lancet. Public health, 2026. discussion
-
“Further studies will be required to more rigorously assess the clinical utility of genetic risk scores for dementia as new therapeutic and preventive agents become available.”
— Validation of newly derived polygenic risk scores for dementia in a prospective study of older individuals; Alzheimer's & Dementia, 2023. conclusion
-
“Ongoing trials, such as TRAILBLAZER-3, enrolling participants only with plasma p-tau217, will further aid in clarifying whether anti-Aβ immunotherapies can potentially be delivered without advanced testing.”
— A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases; Nature Aging, 2023. discussion
-
“Ongoing discussion of Medicare policy and healthcare reform should acknowledge the considerable financial risk currently faced by aging Medicare beneficiaries, and examine reforms that might mitigate these risks.”
— The Burden of Health Care Costs for Patients With Dementia in the Last 5 Years of Life; Annals of Internal Medicine, 2015. discussion
-
“Prospective clinical implementation studies in real-world settings are needed to characterise the effect of plasma p-tau217 on Alzheimer's disease diagnosis and clinical management.”
— Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis; The Lancet Neurology, 2025. abstract only
-
“However, further work is needed to optimise the intervention for delivery in routine settings.”
— Remote, lower-intensity, multidomain lifestyle intervention for subjective cognitive decline or mild cognitive impairment (APPLE-Tree): a multicentre, single-masked, randomised controlled trial; The Lancet Healthy Longevity, 2025. abstract only
-
“Future research should prioritize high-quality RCTs to isolate the effects of peer support from other intervention components, incorporate maintenance strategies to prolong benefits, and include economic evaluations to inform implementation.”
— Effects of peer support interventions for family caregivers of persons with dementia: A systematic review and meta-analysis; Archives of gerontology and geriatrics, 2026. abstract only
-
“Future independent cost-effectiveness analyses would benefit from head-to-head comparisons using real-world data and greater attention to disparities in dementia research.”
— Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review; Journal of Alzheimer's Disease, 2026. abstract only
Who was studied - diversity and generalisability 49 papers
Authors flag that their sample was narrow and that the result may not transfer. — 52 quoted sentences from 49 separate papers.
-
“Overall, the results highlight that interventions will not only need to be tailored to different countries but also to the unique risk profiles and needs of different groups within countries.”
— Population attributable fractions of modifiable risk factors for dementia: a systematic review and meta-analysis.; Stephan BCM, Cochrane L, Kafadar AH, Brain J, Burton E, Myers B, et al.; Lancet Healthy Longevity, 2024. meta-analysis Discussion · source text
-
“Further research across diverse global settings, particularly in low-resource settings, is essential to confirm these findings and guide tailored interventions.”
— Hearing aid effectiveness and probable dementia risk across 33 countries: A pooled analysis of seven cohorts.; Jiang F, Dong Q, Jayakody DMP, Chen X, Mueller C, Wu B, et al.; Cell Reports Medicine, 2026. Limitations of the study · source text
-
“The precise underlying causes are uncertain and require further study, extending also to underrepresented regions such as low and middle income countries.”
— Time to nursing home admission and death in people with dementia: systematic review and meta-analysis.; Brück CC, Mooldijk SS, Kuiper LM, Sambou ML, Licher S, Mattace-Raso F, Wolters FJ; BMJ, 2025. meta-analysis Geographical and temporal differences in prognosis · source text
-
“Future work should aim to reproduce our findings with larger, and more representative, diverse samples.”
— APOE and Alzheimer's disease and related dementias risk among 12,221 Hispanics/Latinos.; Barral S, Yang Z, Phillips N, Barber RC, Brickman AM, Honig LS, Cieza B, Reyes-Dumeyer D, Mayeux R, Rajabli F, et al.; Alzheimer's & Dementia, 2025. DISCUSSION · source text
-
“However, future work should validate the test in diverse groups to realize its full clinical use.”
— FDA approval of the Lumipulse G PTau217/β-amyloid 1-42 plasma ratio test: a new era in accessible Alzheimer's diagnosis.; Biruk D. Ayalew, Zemichael G. Alemayehu, Tsimona D. Bonger, Brook L. Sime, Yonatan A. Zewdie, Yeamlak T. Tewodros, Sher Bano; Annals of Medicine and Surgery, 2025. editorial Future directions and recommendations · source text
-
“Finally, this study did not formally assess potential interactions between age, race/ethnicity, sex, neighborhood deprivation, and dementia incidence or prevalence, and future work to disentangle intersectionality in these dimensions is clearly needed.”
— Incidence and prevalence of dementia among US Medicare beneficiaries, 2015-21: population based study.; Blass B, Ford CB, Soneji S, Zepel L, Rosa TD, Kaufman BG, Mantri S, Li F, Mac Grory B, Xian Y, et al.; BMJ, 2025. Strengths and weaknesses of study · source text
Show the other 46 quotes in this theme
Biomarker-defined, genetic and clinical subgroups 47 papers
Who benefits, not just whether anyone does. — 56 quoted sentences from 47 separate papers.
-
“While the link between APOE ε2 and ARIA risk remains to be elucidated, these observations suggest that APOE ε2 status may need to be factored into individual risk assessment of hemorrhagic complications following ATTs.”
— Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.; van Etten ES, et al.; Alzheimer's & Dementia, 2026. review Role of immune responses, CAA‐ri, and APOE genotype · source text
-
“Furthermore, the ARM response is reduced in the setting of sporadic AD genetic risk variants such as TREM2 R47H and APOE E4. While it is plausible that the ARM response to beta-amyloid plaques is protective, the precise mechanism remains unclear.”
— APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer's disease.; Nguyen AT, Wang K, Hu G, Wang X, Miao Z, Azevedo JA, Suh E, Van Deerlin VM, Choi D, Roeder K, Li M, Lee EB; Acta Neuropathologica, 2020. Discussion · source text
-
“In this respect, further research is needed to assess differences between the two sexes in elderly people.”
— Association between Mediterranean diet and dementia and Alzheimer disease: a systematic review with meta-analysis.; Nucci D, Sommariva A, Degoni LM, Gallo G, Mancarella M, Natarelli F, et al.; Aging Clinical and Experimental Research, 2024. meta-analysis Discussion · source text
-
“If future studies confirm that Aβ positivity affects SAA results, it is then crucial to develop SAA protocols that are robust to Aβ co-pathology.”
— Diagnostic Performance of the α-Synuclein Seed Amplification Assay for Dementia With Lewy Bodies: A Comparison Across 4 Laboratories.; Kumar R, Gravett S, Jelic V, Lange J, Oftedal L, Ciullini A, Bacınoğlu MB, De Luca CMG, Hamied L, Birck C, et al.; Neurology, 2026. Discussion · source text
-
“Overall, the results highlight that interventions will not only need to be tailored to different countries but also to the unique risk profiles and needs of different groups within countries.”
— Population attributable fractions of modifiable risk factors for dementia: a systematic review and meta-analysis.; Stephan BCM, Cochrane L, Kafadar AH, Brain J, Burton E, Myers B, et al.; Lancet Healthy Longevity, 2024. meta-analysis Discussion · source text
-
“Sex and gender differences should be carefully considered in future studies examining the association or effect of olive oil on cognitive-related outcomes to improve our understanding.”
— Consumption of Olive Oil and Diet Quality and Risk of Dementia-Related Death.; Tessier AJ, Cortese M, Yuan C, Bjornevik K, Ascherio A, Wang DD, Chavarro JE, Stampfer MJ, Hu FB, Willett WC, et al.; JAMA Network Open, 2024. Discussion · source text
Show the other 50 quotes in this theme
Follow-up is too short to know if the effect lasts 42 papers
Papers repeatedly say their own follow-up window cannot answer whether a benefit persists. — 51 quoted sentences from 42 separate papers.
-
“In fact, longitudinal studies may be prone to selection bias, especially in the elderly population, who may be lost to follow-up for various reasons, including death.”
— Association between Mediterranean diet and dementia and Alzheimer disease: a systematic review with meta-analysis.; Nucci D, Sommariva A, Degoni LM, Gallo G, Mancarella M, Natarelli F, et al.; Aging Clinical and Experimental Research, 2024. meta-analysis Discussion · source text
-
“Furthermore, our results on cognitive decline are in accordance with other longitudinal studies showing no association between physical activity and cognitive ageing.”
— Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study.; Sabia S, Dugravot A, Dartigues JF, Abell J, Elbaz A, Kivimäki M, Singh-Manoux A; BMJ, 2017. Strengths and limitations of study · source text
-
“Many studies of cognitive impairment due to RBD and circadian rhythm are extremely small for a comprehensive evaluation, and further longitudinal studies are warranted in the future.”
— Sleep disorders and the risk of cognitive decline or dementia: an updated systematic review and meta-analysis of longitudinal studies.; Zhang J, Ou J, Lu X, Wang T, Dang W, Ding L, Liu Y, Xu J, Yan B, Yu H; Journal of Neurology, 2025. meta-analysis Other sleep disorders and cognitive disorders · source text
-
“Future studies may benefit from strategies to support sustained engagement, such as enhanced technical support and additional check-ins to address challenges.”
— Digital Reminiscence for Predeath Grief Among Family Caregivers of Patients With Dementia: A Pilot Randomized Clinical Trial.; Falzarano FB, Greenfield A, Saviano SC, Kolla S, Korian S, Osso F, Miller J, Whitson HE, Maciejewski PK, Prigerson HG; JAMA Network Open, 2026. randomised controlled trial Discussion · source text
-
“The next steps will be to establish the most effective, cost-effective, and feasible strategies for reducing these risks, that can be sustained within local contexts and achieve the best impacts, at the population level, in the short, medium, and long term.”
— Population attributable fractions of modifiable risk factors for dementia: a systematic review and meta-analysis.; Stephan BCM, Cochrane L, Kafadar AH, Brain J, Burton E, Myers B, et al.; Lancet Healthy Longevity, 2024. meta-analysis Discussion · source text
-
“Although we acknowledge that this was a 12-month-duration study, which may be insufficient to definitively establish long-term clinical benefit in Alzheimer’s disease, it can still yield meaningful insights, and further studies are necessary to fully establish the effectiveness of this drug.”
— Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.; Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z, Ridha B, Raza S, Livingston NR, Frangou E, et al.; Nature Medicine, 2025. randomised controlled trial Discussion · source text
Show the other 45 quotes in this theme
Bigger samples and independent replication 27 papers
More people, and someone else repeating it. — 27 quoted sentences from 27 separate papers.
-
“Due to the exploratory nature of this phase 2b study, these findings need to be confirmed in larger studies.”
— Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.; Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z, Ridha B, Raza S, Livingston NR, Frangou E, et al.; Nature Medicine, 2025. randomised controlled trial Discussion · source text
-
“However, whether the latter was more pronounced in women than in men was not examined and requires further investigation by future studies that are adequately powered to detect sex differences.”
— Type 2 Diabetes as a Risk Factor for Dementia in Women Compared With Men: A Pooled Analysis of 2.3 Million People Comprising More Than 100,000 Cases of Dementia.; Chatterjee S, Peters SAE, Woodward M, et al.; Diabetes Care, 2016. meta-analysis Conclusions · source text
-
“While some US cohort studies have observed a significant association between vision impairment and dementia risk [ , ], other US and European longitudinal studies have failed to replicate these findings [ – ].”
— A comprehensive evaluation on the associations between hearing and vision impairments and risk of all-cause and cause-specific dementia: results from cohort study, meta-analysis and Mendelian randomization study.; Jiang F, Dong Q, Wu S, Liu X, Dayimu A, Liu Y, Ji H, Wang L, Liu T, Li N, et al.; BMC Medicine, 2024. meta-analysis Background · source text
-
“Therefore, future studies with larger numbers of vascular dementia cases are needed.”
— Dose-response association between device-measured physical activity and incident dementia: a prospective study from UK Biobank.; Petermann-Rocha F, Lyall DM, Gray SR, Gill JMR, Sattar N, Welsh P, et al.; BMC Medicine, 2021. Strengths and limitations · source text
-
“Further studies using larger numbers of well-characterized AD patients and neuropathological data will thus be required to more precisely delineate the impact of each of the loci on AD pathology versus other neuropathologies.”
— Consensus meta-analysis of genome-wide association studies for Alzheimer's disease and related dementias.; Bellenguez C, Lambert JC, et al.; Nature Genetics, 2026. meta-analysis Main · source text
Show the other 22 quotes in this theme
Specific exposures, drugs and programmes named as worth testing 25 papers
Where authors do not just say 'more research' but name the thing they think should be tested. — 31 quoted sentences from 25 separate papers.
-
“While red wine, a key contributor of anthocyanin intake, has been shown to be beneficial for both dementia and depression at moderate intakes, , the associations among alcohol intake, depression, and dementia are complex, and future studies are needed to further understand these findings.”
— Flavonoid-Rich Foods, Dementia Risk, and Interactions With Genetic Risk, Hypertension, and Depression.; Jennings A, Thompson AS, Tresserra-Rimbau A, O'Neill JK, Hill C, Bondonno NP, et al.; JAMA Network Open, 2024. Discussion · source text
-
“Furthermore, our results on cognitive decline are in accordance with other longitudinal studies showing no association between physical activity and cognitive ageing.”
— Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study.; Sabia S, Dugravot A, Dartigues JF, Abell J, Elbaz A, Kivimäki M, Singh-Manoux A; BMJ, 2017. Strengths and limitations of study · source text
-
“The role of prolonged sleep duration in the development of dementia remains unclear and is closely associated with age.”
— Sleep disorders and the risk of cognitive decline or dementia: an updated systematic review and meta-analysis of longitudinal studies.; Zhang J, Ou J, Lu X, Wang T, Dang W, Ding L, Liu Y, Xu J, Yan B, Yu H; Journal of Neurology, 2025. meta-analysis Sleep duration and cognitive disorders · source text
-
“Further research is needed to investigate semaglutide's effects in patients with obesity, both with and without T2DM.”
— Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.; Wang W, Wang QQ, Qi X, Gurney M, Perry G, Volkow ND, Davis PB, Kaelber DC, Xu R; Alzheimer's & Dementia, 2024. DISCUSSION · source text
-
“However, this previous analysis was not designed to examine the association of olive oil and diet quality with dementia-related mortality, and therefore the latter remains unclear.”
— Consumption of Olive Oil and Diet Quality and Risk of Dementia-Related Death.; Tessier AJ, Cortese M, Yuan C, Bjornevik K, Ascherio A, Wang DD, Chavarro JE, Stampfer MJ, Hu FB, Willett WC, et al.; JAMA Network Open, 2024. Introduction · source text
-
“Future studies should evaluate the influence of suddenly stopping the GLP-1 analogs on the brain after daily injections for a year.”
— Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.; Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z, Ridha B, Raza S, Livingston NR, Frangou E, et al.; Nature Medicine, 2025. randomised controlled trial Discussion · source text
Show the other 25 quotes in this theme
Whether the association is causal is still open 18 papers
Observational signals that the authors themselves decline to call cause and effect. — 18 quoted sentences from 18 separate papers.
-
“Although the analyses were adjusted for the number of components the participants received, future studies could consider testing intervention components with similar dosage and delivery settings to minimize confounding factors.”
— Multicomponent Intervention for Distressed Informal Caregivers of People With Dementia: A Randomized Clinical Trial.; Kwok JYY, Cheung DSK, Zarit S, Cheung KS, Lau BHP, Lou VW, Cheng ST, Gallagher-Thompson D, Qian M, Chou KL; JAMA Network Open, 2025. randomised controlled trial Strengths and Limitations · source text
-
“Future studies will need to confirm underlying mechanisms and should investigate other eye diseases (observationally and in MR studies), including diabetic retinopathy, optic neuropathy, and other vascular causes of eye disease.”
— Visual Impairment, Eye Conditions, and Diagnoses of Neurodegeneration and Dementia.; Ferguson EL, Thoma M, Buto PT, Wang J, Glymour MM, Hoffmann TJ, et al.; JAMA Network Open, 2024. Discussion · source text
-
“Randomized controlled trials are needed to confirm the observational evidence.”
— Comparative dementia risk with GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors: a population-based cohort study.; Wu CY, Alkabbani W, Shah BR, Kapral MK, Edwards JD, Maxwell CJ, et al.; Alzheimer's Research & Therapy, 2025. Limitations · source text
-
“The study findings need to be interpreted keeping in mind the observational nature of the data.”
— Alcohol consumption and risk of dementia: 23 year follow-up of Whitehall II cohort study.; Sabia S, Fayosse A, Dumurgier J, Dugravot A, Akbaraly T, Britton A, Kivimäki M, Singh-Manoux A; BMJ, 2018. Strengths and limitations of this study · source text
-
“These considerations highlight the need for further research using more rigorous methodologies, such as phase 2 randomized controlled trials with lower attrition and alternative strategies to mitigate assessment‐related biases.”
— A randomized trial of two online platforms for dementia family caregivers: GamePlan4Care and Resources4Care.; Stevens AB, Cho J, Birchfield T, Reese J, Han G, Thorud JL, Ory MG; Alzheimer's & Dementia, 2025. randomised controlled trial DISCUSSION · source text
-
“The cognitive benefits of cataract surgery should be investigated further in randomized trials.”
— Cataract Surgery and Cognitive Benefits in the Older Person: A Systematic Review and Meta-analysis.; Yeo BSY, et al.; Ophthalmology, 2024. meta-analysis abstract only
Show the other 12 quotes in this theme
Long-term safety and harms 14 papers
Adverse effects over a horizon longer than the trial. — 24 quoted sentences from 14 separate papers.
-
“Further study of CAA‐ri may therefore offer a valuable model for exploring the pathophysiological mechanisms of ARIA.”
— Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.; van Etten ES, et al.; Alzheimer's & Dementia, 2026. review Spontaneous hemorrhages and edema · source text
-
“Whether the microglial response is harmful, helpful, or both during disease progression remains unclear.”
— APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer's disease.; Nguyen AT, Wang K, Hu G, Wang X, Miao Z, Azevedo JA, Suh E, Van Deerlin VM, Choi D, Roeder K, Li M, Lee EB; Acta Neuropathologica, 2020. Discussion · source text
-
“Any potential benefits of antipsychotic treatment therefore need to be weighed against the risk of serious harm across multiple outcomes.”
— Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study.; Mok PLH, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA, Camacho EM, van Staa T, Avery AJ, Ashcroft DM; BMJ, 2024. Policy implications · source text
-
“However, the reported variability in sensitivity and specificity values across our 4 laboratories and fair agreement suggest that the next step is to propose international recommendations for the harmonization of the α-syn SAA for clinical use.”
— Diagnostic Performance of the α-Synuclein Seed Amplification Assay for Dementia With Lewy Bodies: A Comparison Across 4 Laboratories.; Kumar R, Gravett S, Jelic V, Lange J, Oftedal L, Ciullini A, Bacınoğlu MB, De Luca CMG, Hamied L, Birck C, et al.; Neurology, 2026. Discussion · source text
-
“Future studies should report more transparently on the impact of ARIA.”
— Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease.; Nonino F, Minozzi S, Sambati L, Del Giovane C, Baldin E, Bassi MC, et al.; Cochrane Database of Systematic Reviews, 2026. meta-analysis Implications for research · source text
-
“Although we observed some harmful effects of APOE4 on lifespan, as observed in ‘the early survival’ and median age at death, which many previous longevity studies primarily evaluate ( ), further studies would be needed to confirm that APOE4 has indeed worse impacts on overall lifespan, compared to APOE3 , as observed in clinical data.”
— APOE2 is associated with longevity independent of Alzheimer's disease.; Shinohara M, Kanekiyo T, Tachibana M, Kurti A, Shinohara M, Fu Y, Zhao J, Han X, Sullivan PM, Rebeck GW, Fryer JD, Heckman MG, Bu G; eLife, 2020. Discussion · source text
Show the other 18 quotes in this theme
The right dose, intensity, frequency and type is unresolved 13 papers
Especially for exercise, diet and other behavioural interventions: something works, but not how much of it. — 15 quoted sentences from 13 separate papers.
-
“However, it remains unclear which specific components or combinations are most effective.”
— Multicomponent Intervention for Distressed Informal Caregivers of People With Dementia: A Randomized Clinical Trial.; Kwok JYY, Cheung DSK, Zarit S, Cheung KS, Lau BHP, Lou VW, Cheng ST, Gallagher-Thompson D, Qian M, Chou KL; JAMA Network Open, 2025. randomised controlled trial Introduction · source text
-
“Of note, some of the higher‐dose cohorts received a single dose of dexamethasone prior to each treatment to minimize infusion reactions; it remains unknown whether this pre‐treatment has any effect on ARIA occurrence, as lower ARIA rates were also observed among participants who did not receive any steroid pre‐treatment.”
— Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.; van Etten ES, et al.; Alzheimer's & Dementia, 2026. review Brainshuttle · source text
-
“Future studies are needed to confirm current findings, explore the effects of different types of exercise training on outcomes in individuals with SVCI, identify moderators of exercise efficacy (e.g., biological sex), and examine the distinct mechanisms by which each exercise modality may exert its benefits.”
— Resistance training and subcortical vascular cognitive impairment: A 12-month randomized trial.; Liu-Ambrose T, Falck RS, Dao E, Crockett RA, Barha CK, Silva NCBS, et al.; Alzheimer's & Dementia, 2026. randomised controlled trial DISCUSSION · source text
-
“Further studies should be carried out adopting a more rigorous methodology (e.g., randomization strategies) to investigate the effectiveness of COTs, especially CT and CR interventions, and attempting to address the existing heterogeneity, including standardizing interventions, and reporting detailed data on treatment protocols and on the frequency and intensity of interventions.”
— The efficacy of cognitive stimulation, cognitive training, and cognitive rehabilitation for people living with dementia: a systematic review and meta-analysis.; Paggetti A, Druda Y, Sciancalepore F, Della Gatta F, Ancidoni A, Locuratolo N, et al.; GeroScience, 2024. meta-analysis Future directions · source text
-
“However, the current evidence falls short in elucidating the precise dose–response relationship between PA and the incidence of dementia, necessitating further research [ ].”
— Dose- and pattern- physical activity is associated with lower risk of dementia.; Wang Y, Li F, Cao S, Jia J; Journal of Prevention of Alzheimer's Disease, 2025. Introduction · source text
-
“Beyond their diagnostic value, future work will undoubtedly focus on whether amyloid and tau PET can identify optimal responders to various treatments and whether the duration of treatment can be calibrated on the basis of longitudinal changes in PET.”
— Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.; Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, Herscovitch P, Kuo PH, Lingler JH, Minoshima S, et al.; Alzheimer's & Dementia, 2025. systematic review FURTHER RESEARCH QUESTIONS · source text
Show the other 9 quotes in this theme
When in life to intervene 13 papers
Midlife, preclinical, or after symptoms - the window is contested. — 13 quoted sentences from 13 separate papers.
-
“Future studies should also consider 3‐5 years of long‐term follow‐up, starting from prodromal DLB (mild cognitive impairment with Lewy bodies MCI‐LB), to provide comprehensive coverage of long‐term observations.”
— Long-term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: An up to 10-year follow-up study.; Xu H, Habich A, Ferreira D, Elisabet L, Westman E, Eriksdotter M; Alzheimer's & Dementia, 2024. DISCUSSION · source text
-
“Although we observed some harmful effects of APOE4 on lifespan, as observed in ‘the early survival’ and median age at death, which many previous longevity studies primarily evaluate ( ), further studies would be needed to confirm that APOE4 has indeed worse impacts on overall lifespan, compared to APOE3 , as observed in clinical data.”
— APOE2 is associated with longevity independent of Alzheimer's disease.; Shinohara M, Kanekiyo T, Tachibana M, Kurti A, Shinohara M, Fu Y, Zhao J, Han X, Sullivan PM, Rebeck GW, Fryer JD, Heckman MG, Bu G; eLife, 2020. Discussion · source text
-
“Future studies in larger community‐based settings may provide additional information on the utility of p‐tau217 in screening for preclinical AD.”
— Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer's disease pathology among cognitively impaired and unimpaired: A systematic review and meta-analysis.; Mohammad Khalafi, William J. Dartora, Laura Beth J. McIntire, Tracy A. Butler, Krista M. Wartchow, Seyed Hani Hojjati, Qolamreza R. Razlighi, Kiarash Shirbandi, Liangdong Zhou, Kewei Chen, Ke Xi, Samprit Banerjee, Nancy Foldi, Silky Pahlajani, Lidia Glodzik, Yi Li, Mony J. de Leon, Gloria C. Chiang; Alzheimer's & Dementia, 2024. meta-analysis Conclusion · source text
-
“Although a recent review assessed prospective longitudinal studies to describe the associations between CR, AD biomarkers, and cognitive/clinical outcomes in participants who were cognitively normal at baseline (i.e., preclinical AD-dementia) (Soldan et al. ), their focus on how CR was related to multiple outcomes including onset of clinical symptoms of MCI, changes in cognition, and changes in AD biomarkers, precluded a quantitative examination and limited conclusions regarding the effect of CR on dementia progression.”
— Cognitive Reserve, Alzheimer's Neuropathology, and Risk of Dementia: A Systematic Review and Meta-Analysis.; Nelson ME, Jester DJ, Petkus AJ, Andel R; Neuropsychology Review, 2021. meta-analysis Focus of the Current Review · source text
-
“Midlife depression has been associated with an increased risk of dementia, but it remains unclear whether this risk is attributable to specific symptoms.”
— Specific midlife depressive symptoms and long-term dementia risk: a 23-year UK prospective cohort study.; Frank P, Singh-Manoux A, Pentti J, Batty GD, Sommerlad A, Steptoe A, et al.; Lancet Psychiatry, 2025. abstract only
Show the other 8 quotes in this theme
Better treatments and interventions still need developing 2 papers
Not whether a thing works, but that no good enough option exists yet. — 2 quoted sentences from 2 separate papers.
-
“Further research is needed into safer drug treatment of behavioural and psychological symptoms of dementia and more efficacious, easy to deliver, initial non-drug treatments.”
— Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study.; Mok PLH, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA, Camacho EM, van Staa T, Avery AJ, Ashcroft DM; BMJ, 2024. Policy implications · source text
Show the other 1 quote in this theme
Combination and multidomain approaches 1 paper
Whether interventions add up, and which ones to combine. — 1 quoted sentence from 1 separate paper.
-
“However, it remains unclear which specific components or combinations are most effective.”
— Multicomponent Intervention for Distressed Informal Caregivers of People With Dementia: A Randomized Clinical Trial.; Kwok JYY, Cheung DSK, Zarit S, Cheung KS, Lau BHP, Lou VW, Cheng ST, Gallagher-Thompson D, Qian M, Chou KL; JAMA Network Open, 2025. randomised controlled trial Introduction · source text
Other open questions 35 papers
Verbatim suggestions that did not fall into any theme above. They are published rather than discarded so the page does not quietly lose a question an author actually raised. — 47 quoted sentences from 35 separate papers.
-
“While these findings suggest that postmortem CSF SAA results may generally be comparable to those obtained from antemortem samples, further research is needed to fully understand the differences.”
— Two-step detection of Lewy body pathology via smell-function testing and CSF α-synuclein seed amplification.; Mastenbroek SE, Collij LE, Vogel JW, Caldera S, Serrano GE, Adler CH, Vargiu CM, Palmqvist S, Barkhof F, Parchi P, et al.; Nature Communications, 2025. Discussion · source text
-
“These factors should be considered in future studies for a more comprehensive evaluation.”
— Long-term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: An up to 10-year follow-up study.; Xu H, Habich A, Ferreira D, Elisabet L, Westman E, Eriksdotter M; Alzheimer's & Dementia, 2024. DISCUSSION · source text
-
“Our report pointing at technical variation in α-syn preparation, experimental conditions, and analysis of SAA results may elucidate several areas for improvement in future studies.”
— Diagnostic Performance of the α-Synuclein Seed Amplification Assay for Dementia With Lewy Bodies: A Comparison Across 4 Laboratories.; Kumar R, Gravett S, Jelic V, Lange J, Oftedal L, Ciullini A, Bacınoğlu MB, De Luca CMG, Hamied L, Birck C, et al.; Neurology, 2026. Discussion · source text
-
“Other biomarkers that seem to be more aligned with tau aggregate pathology – including p-tau262 and p-tau356 for soluble tau assemblies [ ] and MTBR tau for fibrils and tangles [ , ] should be investigated in future studies.”
— Head-to-head comparison of plasma p-tau217 immunoassays for incipient Alzheimer's disease in community cohorts.; Rebecca A. Deek, Wasiu G. Balogun, Xuemei Zeng, Gallen Triana-Baltzer, Tharick A. Pascoal, Hartmuth C. Kolb, Beth Snitz, Ann D. Cohen, Thomas K. Karikari; Alzheimer's Research & Therapy, 2026. Discussion · source text
-
“Other factors underlying this finding should be explored in future studies.”
— Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform.; Sebastian Palmqvist, Noëlle Warmenhoven, Federica Anastasi, Andrea Pilotto, and colleagues (multi-site Swedish, Spanish and Italian collaboration); Nature Medicine, 2025. Discussion · source text
-
“Though we observed a significant reduction in AD risk in a high‐risk population with T2DM and also high comorbidity (43% obesity and 77% hypertension), future studies should explore longer follow‐ups and different populations.”
— Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.; Wang W, Wang QQ, Qi X, Gurney M, Perry G, Volkow ND, Davis PB, Kaelber DC, Xu R; Alzheimer's & Dementia, 2024. DISCUSSION · source text